Royalty Pharma PLC - CL
RPRX59.9700.00% ( 0.000 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Royalty Pharma PLC - CL(RPRX) predict that the Revenue is 925 M (+10.25%), Beat estimate;the EBIT is 889 M (+20.46%), Beat estimate;the EPS is 0.53 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.93B10.25%
0.87B4.19%
+0.05B6.06%
EBITExceed expectations
0.89B20.46%
0.84B13.48%
+0.05B6.98%
EPSMiss expectations
0.5296--
0.67--
-0.1404--%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateAug 5, 2026
Estimate Revenue758.88 M
Estimate EBIT578.62 M
Estimate EPS0.83
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf